Skip to content
StockMarketAgent
Sector pending / In Vitro and In Vivo Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

LON/0RUG stock hub

LON/0RUG has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

LON/0RUGis not in this month’s coverageGet our monthly research letter — no spam
Fair value midpoint
n/a
Fair value pending
Upside to midpoint
n/a
Based on latest report
Confidence
n/a
Data quality and model convergence
Market cap
7.2B
London Stock Exchange
Market data

Live price

Current market quote for this ticker.

Current price
LON/0RUG
In the news

Latest news · LON/0RUG

Recent company headlines from major financial publishers.

Loading
Fetching the latest headlines.
Loading
Fetching the latest headlines.
Loading
Fetching the latest headlines.
Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming
DateLoading
Window
EPS estimate
Revenue estimate
Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E15.7
P25 n/aP50 n/aP75 n/a
Trailing P/E20.9
P25 n/aP50 n/aP75 n/a
ROE9.5
P25 n/aP50 n/aP75 n/a
ROIC13.1
P25 n/aP50 n/aP75 n/a
Benchmarks - 1M
S&P 500n/a
Nasdaq Compositen/a
Dow Jones Industrial Averagen/a
Russell 2000n/a
Indicator catalog

All LON/0RUG market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields
233
Groups with data
11
Currency
EUR
Showing 233 of 233 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

18
MetricValue
Country
France
Country code
UK
Employees
14,894
Employees Change
472%
Employees Change Percent
3.2
Enterprise value
EUR 7.2B
Exchange
London Stock Exchange
Financial currency
EUR
First seen
2026-05-10
Industry
In Vitro and In Vivo Diagnostic Substances
Last refreshed
2026-05-10
Market cap
EUR 7.2B
Price
EUR 71.52
Price currency
EUR
Rev Per Employee
238,376.74x
Sic
2835
Symbol
lon/0RUG
Website
https://www.biomerieux.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

14
MetricValue
Earnings Yield
4.79%
EV Earnings
20.63x
EV/EBIT
11.92x
EV/EBITDA
7.09x
EV/FCF
18.1x
EV/Sales
2.04x
FCF yield
5.46%
Forward P/E
15.75x
P/B ratio
2.02x
P/E ratio
20.89x
P/S ratio
2.04x
PE Ratio10 Y
27.64x
PE Ratio3 Y
32.61x
PE Ratio5 Y
31.5x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

24
MetricValue
EBIT Margin
17.07%
EBITDA Margin
27.76%
FCF margin
11.13%
Gross margin
56.73%
Gross Profit
EUR 2B
Gross Profit Growth
-0.46%
Gross Profit Growth Q
-0.92%
Gross Profit Growth3 Y
2.87%
Gross Profit Growth5 Y
2.21%
Net Income
EUR 346.8M
Net Income Growth
-8.03%
Net Income Growth Q
9.04%
Net Income Growth3 Y
-1.13%
Net Income Growth5 Y
0.59%
Pretax Margin
12.92%
Profit Margin
9.77%
Profit Per Employee
EUR 23,282
ROA
7.66
Roa5y
8.29
ROCE
15.41
ROE
9.54
Roe5y
12.62
ROIC
13.12
Roic5y
14.63

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

25
MetricValue
Cagr10y
7.3%
Cagr15y
8.12%
Cagr1y
-36.73%
Cagr3y
-9.24%
Cagr5y
-5.12%
Div CAGR10
12.05%
Div CAGR3
1.46%
Div CAGR5
34.41%
EPS Growth
-8.24
EPS Growth Q
9.36
EPS Growth3 Y
-1.26
EPS Growth5 Y
0.55
FCF Growth
40.93%
FCF Growth Q
4.99%
FCF Growth3 Y
42.56%
FCF Growth5 Y
21.35%
OCF Growth
18.15%
OCF Growth Q
0.15%
OCF Growth10 Y
3.07%
OCF Growth3 Y
16.81%
OCF Growth5 Y
10.81%
Revenue Growth
2.26x
Revenue Growth Q
-2.5x
Revenue Growth3 Y
2.25x
Revenue Growth5 Y
1.92x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

22
MetricValue
Asset Turnover
EUR 0.72
Assets
EUR 4.9B
Cash
EUR 497.1M
Current Assets
EUR 2.2B
Current Liabilities
EUR 921M
Debt
EUR 402.5M
Debt EBITDA
EUR 0.4
Debt Equity
EUR 0.11
Debt FCF
EUR 1.02
Equity
EUR 3.6B
Interest Coverage
43.97
Liabilities
EUR 1.3B
Long Term Assets
EUR 2.7B
Long Term Liabilities
EUR 360.3M
Net Cash
EUR 94.6M
Net Cash By Market Cap
EUR 1.31
Net Debt EBITDA
EUR -0.1
Net Debt Equity
EUR -0.03
Net Debt FCF
EUR -0.24
Tangible Book Value
EUR 2.6B
Tangible Book Value Per Share
EUR 21.98
WACC
7

Liquidity

Current-asset coverage and working-capital efficiency metrics.

6
MetricValue
Current ratio
2.39
Inventory Turnover
1.76
Net Working Capital
EUR 904.9M
Quick ratio
1.42
Working Capital
EUR 1.3B
Working Capital Turnover
EUR 2.5

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

10
MetricValue
Buyback Yield
-0.06%
Dividend Growth
4.97%
Dividend Growth Years
1%
Dividend per share
EUR 0.76
Dividend Years
19
Dividend Yield
1.06%
Ex Div Date
2025-06-09
Last Dividend
EUR 0.76
Payout Frequency
Annual
Payout Ratio
26.69%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

37
MetricValue
10Y total return
102.24%
1Y total return
-36.71%
200-day SMA
105.2
3Y total return
-25.24%
50-day SMA
88.4
50-day SMA vs 200-day SMA
50under200
5Y total return
-23.12%
All Time High
212.1
All Time High Change
-66.27%
All Time High Date
2017-09-19
All Time Low
15.4
All Time Low Change
364.4%
All Time Low Date
2008-10-10
ATR
2.56
Beta
0.54
Ch YTD
-35.09
High
71.65
High52
128.4
High52 Date
2025-08-21
High52ch
-44.3%
Low
70.9
Low52
68.05
Low52 Date
2026-04-30
Low52ch
5.1%
Ma50ch
-19.1%
Price vs 200-day SMA
-32.02%
RSI
28.98
RSI Monthly
29.79
RSI Weekly
22.28
Sharpe ratio
-1.89x
Sortino ratio
-1.99
Total Return
1%
Tr YTD
-35.09
Tr15y
222.55%
Tr1m
-22.77%
Tr1w
-0.81%
Tr3m
-25.12%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

6
MetricValue
Operating Income
EUR 606.1M
Operating Income Growth
-1.28
Operating Income Growth Q
-2.57
Operating Income Growth3 Y
5.81
Operating Income Growth5 Y
4.34
Operating margin
17.07

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

6
MetricValue
Float
44,619,567%
Net Borrowing
-25,604,938
Shares Insiders
0.05%
Shares Institutions
17.51%
Shares Qo Q
-0.11%
Shares Yo Y
0.06%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

65
MetricValue
Adjusted FCF
EUR 372.2M
Average Volume
64,202.15x
Bv Per Share
30.33
CAPEX
EUR -292.5M
Ch10y
89.37
Ch15y
183.4
Ch1m
-22.77
Ch1w
-0.81
Ch1y
-37.18
Ch3m
-25.12
Ch3y
-27.11
Ch5y
-26.23
Ch6m
-32.91
Change
0.34%
Change From Open
0.94
Close
71.28
Days Gap
-0.6
Depreciation Amortization
376,202,281
Dollar Volume
3,590,933.6
Earnings Date
2026-07-28
EBIT
EUR 606.1M
EBITDA
EUR 985.5M
EPS
EUR 2.91
F Score
7
FCF
EUR 395.3M
FCF EV Yield
5.53x
Financing CF
-135,566,749
Fiscal Year End
December
Founded
1,963
Goodwill
629,570,062.3
Graham Number
52.01515
Graham Upside
-27.02
Income Tax
EUR 112.4M
Investing CF
-402,774,568
Is Primary Listing
0
Last Earnings Date
2026-02-27
Last Report Date
2025-12-31
Last Split Date
2017-09-20
Last Split Type
Forward
Lynch Fair Value
EUR 17.06
Lynch Upside
-76.07
Ma150
100.3
Ma150ch
-28.69%
Ma20
79.98
Ma20ch
-10.58%
Net CF
107,301,867
Next Earnings Date
2026-07-28
Open
70.85
P FCF Ratio
18.33
P OCF Ratio
10.53
Payment Date
2025-06-11
Position In Range
82.25
Ppne
1,433,530,512.9
Price Date
2026-05-08
Price EBITDA
EUR 7.35
Ptbv Ratio
2.79
Relative Volume
0.78x
Revenue
3,550,383,232x
SBC By Revenue
0.65x
Share Based Comp
23,117,882
Tax By Revenue
3.16x
Tax Rate
24.5%
Tr6m
-32.91%
Volume
50,211
Z Score
7.11
Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate
n/a
Named kill scenarios are reviewed before any bullish rating can stand.
Moat score
n/a
Business quality stays separate from stock attractiveness.
Forward P/E
n/a
Valuation uses the full report model stack, not a single multiple.
Next action
Research pending
Final action steps are kept in the recommendation tab.
Income

LON/0RUG dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield
+1.1%
$0.76 annual per share
Payout ratio
+26.7%
Share of earnings returned as dividends. Below 60% is generally sustainable.
5Y dividend CAGR
+34.4%
1 consecutive years of growth
Total shareholder yield
+1.0%
Next ex-dividend date: 2025-06-09
Performance

LON/0RUG stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

1Y total return
-36.7%
S&P 500 1Y: n/a
3Y total return
-25.2%
S&P 500 3Y: n/a
5Y total return
-23.1%
S&P 500 5Y: n/a
10Y total return
+102.2%
S&P 500 10Y: n/a
Ownership

Who owns LON/0RUG?

Insider, institutional, and short-interest positioning.

Institutional ownership
+17.5%
Share of float held by funds and institutions
Insider ownership
+0.1%
Stake held by company insiders. Higher generally signals alignment.
Short interest
n/a
Float sold short by bearish positioning
Y/Y dilution
+0.1%
Negative means the company is buying back shares.
Technical

LON/0RUG momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)
29.0
Below 30: short-term oversold
Price vs 200-day MA
-32.0%
50/200-day relationship not available
Beta (5Y)
0.54
Less volatile than the market
Sharpe ratio
-1.89
Risk-adjusted return — higher is better; >1.0 is solid.
Questions

About LON/0RUG

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0RUG stock rating?

lon/0RUG is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0RUG analysis?

The full report lives at /stocks/lon/0RUG/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0RUG?

The latest report frames lon/0RUG around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0RUG page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.

lon/0RUG stock profile: metrics, valuation and analysis | Agent AI Rynku Akcji